Volume 14 Supplement 7

Proceedings of the 10th Edition of the Scientific Days of the National Institute for Infectious Diseases "Prof Dr Matei Bals"

Open Access

Non-invasive assessment of liver fibrosis through FibroMeter in patients with chronic viral hepatitis B and C

  • Oana Săndulescu1, 2Email author,
  • Anca Streinu-Cercel1, 2,
  • Gabriela Ceapraga2,
  • Mara Constantinescu1 and
  • Adrian Streinu-Cercel1, 2
BMC Infectious Diseases201414(Suppl 7):P50

https://doi.org/10.1186/1471-2334-14-S7-P50

Published: 15 October 2014

Background

Since the advent of non-invasive methods for liver fibrosis assessment, liver biopsy has been increasingly replaced with liver stiffness measurements or with computed scores based on serum biomarkers, particularly for monitoring viral infections such as HBV [1] or HCV [2, 3].

Methods

We performed a screening study using FibroMeter (Echosens, Paris) to determine the stage of fibrosis and the necroinflammatory status in a cohort of patients with chronic HBV and HCV infection under surveillance in a tertiary care hospital in Bucharest, Romania.

Results

We analyzed data from 87 patients, 68 (78.2%) of which had chronic HBV infection and 19 (21.8%), chronic HCV infection. The median age was 44.9±15.0 (range 17-75). The mean body mass index (BMI) was 26.0±3.6 in the HBV group and 26.7±3.2 in the HCV group. Overall, 36 patients (41.4%) had normal BMI, another 36 (41.4%) had a BMI equivalent for overweight status, and 15 (17.2%) had grade I obesity.

The distribution of FibroMeter results was: F0-F1: 8 (9.2%), F1: 2 (2.3%), F1-F2: 43 (49.4%), F2: 11 (12.6%), F2-F3: 8 (9.2%), F3: 7 (8.0%), F3-F4: 8 (9.2%). The distribution of the necroinflammatory activity was: A0-A1: 16 (18.4%), A1-A2: 52 (59.8%), A2-A3: 19 (21.8%). We identified no statistically significant differences between patients with HBV and HCV regarding mean fibrosis scores (p=0.476) or mean necroinflammatory activity scores (p=0.681).

Conclusion

The patients included in this study had varied ages and characteristics. FibroMeter classified most of them as F1-F2 but descriptive data should be interpreted in clinical context and potential confounding factors should be identified on a case-by-case basis.

Declarations

Acknowledgement

This paper is partially supported by the Sectoral Operational Programme Human Resources Development (SOP HRD), financed from the European Social Fund and by the Romanian Government under the contract numbers POSDRU/159/1.5/S/137390.

Authors’ Affiliations

(1)
Carol Davila University of Medicine and Pharmacy
(2)
National Institute for Infectious Diseases "Prof. Dr. Matei Balş"

References

  1. Streinu-Cercel O, Streinu-Cercel A, Preoțescu LL, Streinu-Cercel A: Entecavir as specific antiviral therapy in selected cases of severe acute hepatitis B. GERMS. 2012, 2: 18-22. 10.11599/germs.2012.1009.PubMed CentralView ArticlePubMedGoogle Scholar
  2. Streinu-Cercel A: Hepatitis C in the interferon-free era. GERMS. 2013, 3: 114-10.11599/germs.2013.1044.PubMed CentralView ArticlePubMedGoogle Scholar
  3. Poynard T, Munteanu M, Deckmyn O, Ngo Y, Drane F, Castille JM, Housset C, Ratziu V, Imbert-Bismut F: Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population. J Hepatol. 2012, 57: 541-8. 10.1016/j.jhep.2012.04.025.View ArticlePubMedGoogle Scholar

Copyright

© Săndulescu et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement